GlaxoSmithKline’s Lamictal Obtains MHLW Approval
This article was originally published in PharmAsia News
Executive Summary
GlaxoSmithKline announced Oct. 16 it obtained a new drug approval for epilepsy drug Lamictal (lamotrigine)from Japan's Ministry of Health, Labor and Welfare. The drug is the first epilepsy drug in Japan that is indicated to treat patients from children to seniors and patients with intractable epilepsy. GSK plans to launch the drug in early December. (Click here for more - Japanese language
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.